Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

InSilico Medicine (ISM HK): AI-Powered Drug Discovery Drives 2025 Result; Signs New Deal with Lilly

InSilico Medicine (ISM HK): Firing on Both Cylinders

Insilico Medicine IPO: Shortening Drug Discovery Period Through AI-Driven Platform Holds Promise

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/insilico-medicine-cayman-topco" target="_blank" data-smartkarma-citation="entities:39890:1" rel="noopener">Insilico Medicine (3696 HK)</a>'s lead asset rentosertib has demonstrated potential for biological age reversal. Data from Phase 2a trial shows 3–4 years reversal in biological age.  </li>
<li>Recently, the company has announced 1H26 result, with revenue increasing 287% YoY to $106M, and achieved its first profitable half-year since listing, with an adjusted net profit of $36M.</li>
<li>Execution of additional strategic collaborations to maximize the application and commercial opportunity of Pharma.AI platform will be the near-term catalyst.</li>
</ul>



Insilico Medicine (3696 HK)'s lead asset rentosertib has demonstrated potential for biological age reversal. Data from Phase 2a trial shows 3–4 years reversal in biological age.  
Recently, the company has announced 1H26 result, with revenue increasing 287% YoY to $106M, and achieved its first profitable half-year since listing, with an adjusted net profit of $36M.
Execution of additional strategic collaborations to maximize the application and commercial opportunity of Pharma.AI platform will be the near-term catalyst.


InSilico Medicine (3696 HK): Pipeline Is Progressing; 1H Sales Jump 4x on BD Deals; Turns Profitable